Metojectpen

Methotrexate, the active ingredient in Metojectpen, is an antimetabolite (folate antagonist) presented as a subcutaneous injection for systemic use. It is employed to manage autoimmune disorders and certain malignancies in adult patients. GNH USA supplies Metojectpen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Methotrexate is used across several disease families, primarily as an immunomodulator and antineoplastic agent. - Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: decreases skin cell proliferation and improves plaque lesions. - Severe eczema: mitigates severe inflammatory skin eruptions. - Certain leukemias and lymphomas: interferes with malignant cell replication. - Gestational trophoblastic disease: promotes resolution of abnormal trophoblastic tissue. - Ectopic pregnancy: facilitates medical management by inhibiting trophoblastic growth.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea or vomiting: mild gastrointestinal upset. - Fatigue: generalized tiredness. - Mouth sores: ulceration of oral mucosa. - Elevated liver enzymes: mild hepatic irritation. - Low blood counts: mild leukopenia or anemia. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Severe liver toxicity: potential hepatitis or fibrosis. - Pulmonary fibrosis: interstitial lung disease with dyspnea. - Myelosuppression: profound neutropenia or pancytopenia. - Renal impairment: acute kidney injury. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Methotrexate requires careful monitoring and patient education to minimise risks. - Pregnancy contraindication: drug is teratogenic and must not be used in pregnancy (Category X). - Liver monitoring: perform baseline and periodic liver function tests. - Renal function: assess creatinine clearance before initiation and during therapy. - Blood counts: conduct regular complete blood counts to detect myelosuppression. - Drug interactions: avoid concurrent use with high‑dose NSAIDs or other folate antagonists. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several drug classes, necessitating vigilance.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (high‑dose NSAIDs): increase methotrexate toxicity. - Proton pump inhibitors (omeprazole, esomeprazole): may elevate serum levels. - Trimethoprim‑sulfamethoxazole: augments risk of bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Azathioprine or mycophenolate: additive immunosuppression. - Penicillins (high‑dose): may reduce renal clearance of methotrexate. - Live vaccines: risk of infection due to immunosuppression.